[Treatment of Mild-to-moderate Bronchial Asthma (Heat Wheezing Syndrome) Patients at Acute Onset with Western Medicine Combined Danlong Oral Liquid: a Multi-center, Randomized Double- blinded, Positive-controlled Clinical Trial].

OBJECTIVE: To observe the efficacy and safety of Danlong Oral Liquid (DOL) combined Western medicine (WM) in treating mild-to-moderate bronchial asthma patients (heat wheezing syndrome) at acute onset. METHODS: Totally 480 mild-to-moderate bronchial asthma patients (heat wheezing syndrome) at acute onset were randomly assigned to two groups in the ratio 3:1, the treatment group (360 cases) and the control group (120 cases). All patients received basic WM treatment. Patients in the treatment group took DOL, 10 mL each time, 3 times per day for 7 days in total, while those in the control group took Kechuanning Oral Liquid (KOL) , 10 mL each time, 3 times per day for 7 days in total. Efficacy for asthma symptoms, lung functions and scores of TCM syndrome and/or main symptoms were evaluated. RESULTS: The percentage of clinical control and significant effectiveness of asthma symptoms in the treatment group was significantly higher than that of the control group (77.36% vs 56.07%, P < 0.01). The percentage of clinical control and significant effectiveness of lung functions in the treatment group was significantly higher than that of the control group (74.28% vs 50.00%, P < 0.01). The anterior-posterior difference in scores of TCM syndrome was significantly superior in the treatment group than in the control group (-11.26 ± 4.70 vs -9.21 ± 5.09, P < 0.01). The anterior-posterior difference in scores of main symptoms was significantly better in the treatment group than in the control group (-6.58 ± 3.08 vs -5.16 ± 3.45, P < 0.01). The incidence of adverse reactions was significantly lower in the treatment group than in the control group [1.73% (6/346 cases) vs 10.17% (12/118 cases) , P < 0.05]. CONCLUSION: DOL combined WM was superior to KOL in treating mild-to-moderate bronchial asthma patients (heat wheezing syndrome) at acute onset.

[Correlation between pulmonary function indexes and survival time in patients with advanced lung cancer].

BACKGROUND: To those patients with advanced lung cancer, the ultimate objective is to improve the curative effect and quality of life, lung function indexes are an important factor. We investigate the change of lung function and the relationship between pulmonary function indexs and survival time in patients with advanced lung cancer. METHODS: Lung function was detected in 59 cases with lung cancer and 63 normal controls. The relationship between pulmonary function indexs and survival time was analyzed. RESULTS: There was significant difference in ventilation function and diffusing capacity between in lung cancer group and control group. Vital capacity (VC), forced expiratory volume in one second (FEV1), forced vital capacity (FVC), peak expiratory flow (PEF), peak expiratory flow% (PEF%), maximal ventilatory volume (MVV) were positively correlated with survival time in patients with advanced lung cancer (r=0.29, 0.28, 0.28, 0.27, 0.26, 0.28, P<0.05), residual volume/total lung capacity was negatively correlated with survival time (r=-0.31, P<0.05). CONCLUSIONS: The lung function decreases in the patients with lung cancer. VC, FEV1, FVC, PEF, PEF%, MVV, residual volume/total lung capacity were correlated with survival time in patients with advanced lung cancer. The pulmonary function indexs were important marker of prognosis in patients with lung cancer.

[The study of prethrombotic state in patients with lung cancer.].

BACKGROUND: The prethrombotic state can be observed in advanced lung cancer patients. The aim of this study is to investigate the relationship between coagulation and fibrinolysis marks on pathophysiological characteristics and prognosis in patients with lung cancer. METHODS: The coagulation and fibgrinolysis marks were detected in sixty patients with lung cancer and twenty normal controls. RESULTS: The D-dimer, fibrinogen degradation products, plasma fibrinogen were significantly higher than those of normal controls. The plasma antithrombin III was significantly lower than those of normal controls. All marks in patients with lung cancer were not related to age, sex, histological classification, the size of the primary tumors, P-TNM stages, distant metastasis. The plasma levels of D-dimer and fibrinogen in patients with lung cancer were negatively correlated to survival. CONCLUSIONS: The patients with lung cancer have abnormal coagulation and fibrinolysis state, these contribute to hypercoagulability state and thrombi. The plasma levels of D-dimer and fibrinogen in patients with lung cancer were correlated with prognosis. The anticoagulability medicine treatment are benefit for the patients with lung cancer.

[Matrine and anti-tumor drugs in inhibiting the growth of human lung cancer cell line].

OBJECTIVE: To study the activities of matrine and anti-tumor drugs on SPCA/I human lung adenocarcinoma cell line. METHODS: Suppression effects of different concentrations of matrine and matrine combined with anti-tumor drugs on lung cancer cells were measured by methyl thiazolyl tetrazolium (MTT) colorimetric assay. RESULTS: Different concentrations of matrine could inhibit the growth of SPCA/I human lung adenocarcinoma cells and there was a positive correlation between the inhibition rate and the drug concentration. Different concentrations of matrine combined with anti-tumor drugs had higher growth inhibition rate than anti-tumor drugs alone. CONCLUSION: Matrine has direct growth suppression effect on SPCA/I human lung adenocarcinoma cells and matrine combined with anti-tumor drugs shows a significant synergistic effect on tumor cells.